Skip to main content
OpenTrials
Completed

NCT Number: NCT05630326

Association Between COVID-19 and UTIs Caused by ESBL Organism in Infants

Urinary tract infections (UTIs) in infants and young children are one of the most common bacterial infections, usually febrile illness without source, frequently due to Enterobacteriaceae, mainly Escherichia coli.

Multidrug-resistant organisms including extended-spectrum beta-lactamase (ESBL) producing bacteria are becoming more prevalent. Due to the risk factors of ESBL-producing organisms in community-acquired (CA)-UTIs in infants in QATAR and Arab countries are still not studied because of the limited therapeutic options. hence, the importance of this study is to get knowledge about how to decrease the rapidly increasing in ESBL- producing bacteria, in infants, and to use antibiotics in a suitable guideline.so, The aim of this retrospective case-control study is to determine the clinical manifestations, and investigations of urinary tract infections among infants and the association with COVID-19 infection, in pediatric emergency centers at Hamad General Hospital - Qatar. From 1st January 2015 till 1st January 2022.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Renal Insufficiency Acute Kidney Injury Chronic Disease Disease Attributes Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Kidney Diseases Kidney Failure, Chronic Male Urogenital Diseases Pathologic Processes Pathological Conditions, Signs and Symptoms Renal Insufficiency, Chronic Urogenital Diseases Urologic Diseases

Age range

Up to 1 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Hamad Medical Corporation

Doha, Qatar

About this study

In this retrospective, case-control study investigators will include all infants (0-1 year) with UTIs who were treated at Hamad General Hospital, pediatric division- PEC Doha, Qatar, using the electronic medical records from 1st January 2015 till January 1st, 2022, diagnosed by a positive urine culture. Investigators will look for the clinical manifestations, radiological and laboratory findings, renal scarring, ESBL-organisms, prevalence, median age, gender, and ethnic background. Participants are divided into two groups: early infancy and late infancy, ESBL UTIs and non-ESBL UTIs, and upper UTIs and lower UTIs. Finally, UTIs ESBL with COVID-19 and without COVID_19.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • All infants with UTIs who had been treated

Exclusion criteria

  • Patient with a mixed urine culture.

Treatment and study plan

comparing, prevalence

Other

Comparing infants with UTIs caused by ESBL organism, or non ESBL organism.

Other names: Data on clinical and laboratory findings are reviewed from medical records for details

Assessment

Other

comparing infants with UTIs caused by ESBL organism, or non ESBL organism.

association

Other

comparing ESBLUTI with COVID-19 and ESBL UTI without COVID-19

Evaluation

Other

comparing ESBLUTI with COVID-19 and ESBL UTI without COVID-19

Primary outcomes

  1. Assessment risk factors , prevalence, and the relation between ESBL UTI and COVID-19 infection of all infants with ESBL- UTIs

    Time frame: 1year

Sponsors and collaborators

Lead sponsor

Hamad Medical Corporation

Industry

Registry information

Official study title

Clinical, Laboratory, and Radiological Characteristics of Urinary Tract Infections in Infants With COVID-19

Acronym: ABCUCEOI

Important dates

Study start
2023
Primary completion
2023
Study completion
2023
First posted
Nov 29, 2022
Registry last updated
Jul 27, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.